- Conditions
- Neoplasms
- Interventions
- Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, Dostarlimab, GSK6097608
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • St Louis, Missouri • The Bronx, New York + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neoplasms
- Interventions
- GSK6097608, Dostarlimab, Cobolimab, Belrestotug
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Dallas, Texas + 2 more
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Plantation, Florida • Albuquerque, New Mexico • Chattanooga, Tennessee + 1 more